Global Leukemia Therapeutics Market Expected to Reach $21.5…

Leukemia Therapeutics Market Expected to Reach $21.57 Billion by 2027, Fueled by Rising Prevalence of Leukemia

Global Leukemia Therapeutics Market Expected to Reach $21.57 Billion by 2027, Fueled by Rising Prevalence of Leukemia

The Business Research Company’s Leukemia Therapeutics Global Market Report 2023 – Market Size, Trends, And Global Forecast 2023-2032

The market size of the leukemia therapeutics is expected to grow to $21.57 billion in 2027 at a CAGR of 7.3%.”

— The Business Research Company

LONDON, GREATER LONDON, UK, November 17, 2023 / — The global leukemia therapeutics market, valued at $15.16 billion in 2022, is projected to reach $16.25 billion in 2023, exhibiting a compound annual growth rate (CAGR) of 7.2%. Despite the disruptive impacts of the Russia-Ukraine conflict and the lingering repercussions of the COVID-19 pandemic, the market is anticipated to expand further, achieving a projected valuation of $21.57 billion by 2027. The market growth is primarily driven by the escalating prevalence of leukemia worldwide, necessitating increased access to advanced medical treatments and therapeutics.

Growing Prevalence of Leukemia Stimulates Market Demand

The global increase in the occurrence of leukemia, a form of blood cancer originating in the bone marrow, has significantly contributed to the expansion of the leukemia therapeutics market. Improved availability and accessibility of treatment options for leukemia patients globally have amplified the demand for advanced leukemia therapeutics. Notably, the National Cancer Institute reported a rise in the number of new leukemia cases in the United States, with the count increasing from 60,530 cases in 2020 to 61,090 cases in 2021.

Explore comprehensive insights into the global leukemia therapeutics market with a detailed sample report:

Key Players and Combination Therapies

Prominent industry players such as Novartis International AG and Bristol Myers Squibb are actively engaged in the development and introduction of combination therapies to enhance leukemia treatment outcomes. By combining multiple therapeutic modalities, such as immunotherapies and targeted therapies, these companies aim to provide more effective and comprehensive treatment options, promising long-term survival benefits not achievable with conventional approaches. Notably, in September 2021, the clinical research team at the US-based Dana-Farber Cancer Institute reported the efficacy of a combination therapy involving three molecularly targeted drugs. This combination, featuring an inhibitor of BCL-2 (venetoclax), a second-generation inhibitor of BTK (acalabrutinib), and a CD20 inhibitor (obinutuzumab), has demonstrated effectiveness against chronic lymphocytic leukemia (CLL).


• Treatment Type: Chemotherapy, Immunotherapy, Targeted Therapy, Other Treatments
• Type of Leukemia: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Types of Leukemia
• Molecule Type: Small Molecules, Biologics
• End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users

Geographical Insights: North America Leads Market, Asia-Pacific Witnesses Rapid Growth

North America emerged as the largest region in the leukemia therapeutics market in 2022, with Asia-Pacific expected to showcase the fastest growth in the forecast period. To gain comprehensive insights into regional dynamics, market trends, and growth opportunities, access the complete report.

Access the complete report for an in-depth analysis of the global leukemia therapeutics market:

Leukemia Therapeutics Global Market Report 2023 from TBRC covers the following information:

• Market size date for the forecast period: Historical and Future
• Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
• Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Leukemia Therapeutics Global Market Report 2023 by The Business Research Company is the most comprehensive report that provides insights on leukemia therapeutics market size, leukemia therapeutics market drivers and trends, leukemia therapeutics market major players, leukemia therapeutics market competitors’ revenues, leukemia therapeutics market positioning, and leukemia therapeutics market growth across geographies. The leukemia therapeutics market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Acute Myeloid Leukemia Global Market Report 2023

Chronic Lymphocytic Leukemia Treatment Global Market Report 2023

Anemia And Other Blood Disorder Drugs Global Market Report 2023

About The Business Research Company
The Business Research Company has published over 3000+ detailed industry reports, spanning over 3000+ market segments and 60 geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database
The Global Market Model, The Business Research Company’s flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293

Check out our:
Healthcare Blog:
Global Market Model:

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
Visit us on social media:

Healthcare Industry Overview with Market Research

Source link